X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ASTRAZENECA PHARMA SUN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 37.6 161.7 23.3% View Chart
P/BV x 4.0 25.1 16.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 SUN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-14
SUN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs7011,285 54.5%   
Low Rs433634 68.3%   
Sales per share (Unadj.) Rs110.4189.6 58.2%  
Earnings per share (Unadj.) Rs11.0-0.2 -5,391.7%  
Cash flow per share (Unadj.) Rs17.23.8 448.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.868.6 231.4%  
Shares outstanding (eoy) m2,399.2625.00 9,597.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.15.1 101.4%   
Avg P/E ratio x51.6-4,712.7 -1.1%  
P/CF ratio (eoy) x32.9249.6 13.2%  
Price / Book Value ratio x3.614.0 25.5%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,02123,988 5,669.7%   
No. of employees `00017.81.6 1,141.1%   
Total wages/salary Rs m53,6711,605 3,344.8%   
Avg. sales/employee Rs Th14,890.93,040.2 489.8%   
Avg. wages/employee Rs Th3,017.11,029.2 293.1%   
Avg. net profit/employee Rs Th1,480.6-3.3 -45,348.0%   
INCOME DATA
Net Sales Rs m264,8954,740 5,588.8%  
Other income Rs m8,38892 9,107.1%   
Total revenues Rs m273,2824,832 5,655.9%   
Gross profit Rs m56,081-130 -43,205.9%  
Depreciation Rs m14,998101 14,820.6%   
Interest Rs m5,1760-   
Profit before tax Rs m44,295-139 -31,889.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505139 -6,843.1%   
Tax Rs m8,4525 166,049.1%   
Profit after tax Rs m26,338-5 -517,444.0%  
Gross profit margin %21.2-2.7 -773.1%  
Effective tax rate %19.1-3.7 -520.7%   
Net profit margin %9.9-0.1 -9,258.5%  
BALANCE SHEET DATA
Current assets Rs m316,3592,726 11,603.5%   
Current liabilities Rs m198,6432,435 8,157.8%   
Net working cap to sales %44.46.1 722.8%  
Current ratio x1.61.1 142.2%  
Inventory Days Days9574 128.6%  
Debtors Days Days10841 264.2%  
Net fixed assets Rs m213,1781,035 20,590.9%   
Share capital Rs m2,39950 4,798.6%   
"Free" reserves Rs m378,606942 40,174.7%   
Net worth Rs m381,0061,716 22,203.1%   
Long term debt Rs m17,7210-   
Total assets Rs m643,0284,156 15,472.3%  
Interest coverage x9.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.41.1 36.1%   
Return on assets %4.9-0.1 -4,001.5%  
Return on equity %6.9-0.3 -2,330.5%  
Return on capital %10.00-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m40,816375 10,896.0%   
Fx outflow Rs m30,143470 6,411.4%   
Net fx Rs m10,673-96 -11,170.1%   
CASH FLOW
From Operations Rs m39,072-8 -482,364.2%  
From Investments Rs m-33,708-146 23,135.3%  
From Financial Activity Rs m-15,393862 -1,785.3%  
Net Cashflow Rs m-7,359709 -1,038.7%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 15.7 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 12,856 1,034.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - NOVARTIS COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS